Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic targeting ...
Arrowhead (ARWR) announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference, or ...
The share price in Arrowhead Pharmaceuticals Inc. jumped by more than 48% in the two months since it hit its lowest value of the past year. On Oct. 10, ...
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily ...
Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders should be happy to see the share price up 11% in the ...
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its price target trimmed by Citigroup from $27.00 to $26.00 in a ...
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report). The ...
Arrowhead Pharmaceuticals develops medicines that ... therapeutics leverage this natural pathway of gene silencing. This news release contains forward-looking statements within the meaning of ...
GlobalData on MSN14d
Arrowhead and Sarepta link for rare genetic disease treatmentsArrowhead has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics for rare genetic disease ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback